CORT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
340.5M
+32.9%
256.1M
+55.3%
164.9M
-18.4%
202.1M
-2.7%
207.6M
Cost of Revenue
4.6M
+13.5%
4.1M
+40.9%
2.9M
+13.3%
2.5M
-44.6%
4.6M
Gross Profit
335.9M
+33.2%
252.1M
+55.6%
162.0M
-18.8%
199.6M
-1.7%
203.0M
Operating Expenses
221.1M
+4.9%
210.8M
-0.4%
211.6M
+8.5%
195.1M
+1.2%
192.8M
R&D
56.7M
+5.2%
53.9M
-18.7%
66.3M
+2.2%
64.9M
-5.8%
68.8M
SG&A
164.4M
+4.8%
156.9M
+7.9%
145.4M
+11.6%
130.2M
+5.0%
124.0M
Operating Income
114.7M
+177.8%
41.3M
+183.3%
-49601000
-1205.4%
4.5M
-56.1%
10.2M
EBITDA
115.8M
+174.5%
42.2M
+186.0%
-49003000
-1126.0%
4.8M
-55.3%
10.7M
Net Income
126.8M
+194.9%
43.0M
+235.3%
-31761000
-230.8%
24.3M
+23.5%
19.7M
EPS (Basic)
$1.17
+192.5%
$0.40
+233.3%
$-0.30
-230.4%
$0.23
+21.1%
$0.19
EPS (Diluted)
$1.01
+180.6%
$0.36
+220.0%
$-0.30
-250.0%
$0.20
+25.0%
$0.16
Shares (Diluted)
123.2M
+4.1%
118.4M
+13.4%
104.4M
-13.1%
120.2M
+0.6%
119.4M
Corcept Therapeutics (CORT) — Financials